{"id":"sirolimus-and-oseltamivir","safety":{"commonSideEffects":[{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Sirolimus inhibits the mTOR pathway, reducing T-cell proliferation and promoting autophagy, which may enhance antiviral immunity and reduce excessive inflammatory responses. Oseltamivir inhibits influenza neuraminidase, preventing viral release from infected cells. The combination is hypothesized to provide both direct antiviral activity and immunomodulation to improve outcomes in severe viral infections.","oneSentence":"This combination uses sirolimus (an mTOR inhibitor) to suppress immune responses and promote autophagy, while oseltamivir (a neuraminidase inhibitor) blocks viral replication of influenza.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:54.965Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe influenza or COVID-19 (investigational combination therapy)"}]},"trialDetails":[{"nctId":"NCT03901001","phase":"PHASE3","title":"Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-08","conditions":"Influenza","enrollment":160},{"nctId":"NCT01620307","phase":"PHASE2","title":"Rapamune Improves Outcomes of Severe H1N1 Pneumonia","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2009-06","conditions":"H1N1 Pneumonia, Hypoxemia","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"sirolimus and oseltamivir","genericName":"sirolimus and oseltamivir","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses sirolimus (an mTOR inhibitor) to suppress immune responses and promote autophagy, while oseltamivir (a neuraminidase inhibitor) blocks viral replication of influenza. Used for Severe influenza or COVID-19 (investigational combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}